

**REVIEW ARTICLE****EXTRAPULMONARY SMALL CELL CARCINOMA: CURRENT STATUS AND STRATEGY****BP Rauniyar^{1*}, KR Devkota¹**¹ B. P. Koirala Memorial Cancer Hospital, Bharatpur, Chitwan, Nepal

**Correspondence to: Dr. Bhola Prasad Rauniyar, Department of Medical Oncology, B. P. Koirala Memorial Cancer Hospital, Bharatpur, Chitwan, Nepal.
Email: novartis.bpkmch@yahoo.com*

ABSTRACT

Extrapulmonary small cell carcinoma is very rare. Its prognosis is poor and there is no established treatment modality. It has been considered as a distinct clinicopathological entity. It is distinct from small cell carcinoma of the lung, though it shares similar clinicopathologic features to the latter. It has a similar staging and treatment modality. The aim is to review existing studies and provide new results on diagnosis and current management strategy for patients with Extrapulmonary small cell carcinoma. The study involves the review of the literature using the electronic database MEDLINE and hand searching of journals. The outcome measures are addressed and analyzed. Studies have shown wide variations of treatment modalities adopted and the outcome observed. Almost all studies are of inadequate power to establish standard treatment modality. Multi-centre studies are required to institutionalize standard treatment modality.

Key words: ESC (Extrapulmonary small cell carcinoma), PCI (prophylactic cranial irradiation), SCC (small cell carcinoma).

DOI: <http://dx.doi.org/10.3126/jcmc.v5i4.16571>

INTRODUCTION

Extrapulmonary small cell carcinoma (ESC) may occur in many sites. It is rare. Its prognosis is poor and there is no established treatment. It has been considered as a distinct clinicopathological entity from small cell carcinoma (SCC) of the lung. It has a similar staging and treatment modality. The aim of the current study is to report the clinical features, management and natural courses of the cases with ESC. Few data are available on ESC in literature.

DISCUSSION

Undifferentiated small cell carcinoma (SCC) is an aggressive lung tumour accounting for 15% of all lung cancers.¹ Extrapulmonary small cell carcinomas (ESCs) are uncommon malignant neoplasms with

a reported incidence of 0.1 to 0.4% of all cancers.² ESC was first described in 1930 in mediastinal glands.⁴ Approximately 2.5% of all SCC's arise in extrapulmonary sites² including large bowel,⁵ kidney,⁶ bladder,⁷ breast,^{8,9} esophagus^{10,11} stomach,¹² urethra,¹³ uterine neck,¹⁴ appendix,¹⁵ liver,¹⁶ common bile duct,¹⁷ gall bladder,¹⁸ mediastinum,¹⁹ and even in unusual sites including submandibular gland,²⁰ bone²¹ and pancreas.²² Age and sex distribution for ESC are similar to that seen in adenocarcinoma of the colon.³

The morphologic, immunohistochemical and ultrastructure are similar to those described in pulmonary small cell carcinoma (PSCC). The differential diagnosis includes PSCC, small blue

cell tumors, metastatic melanoma, lymphoma and poorly differentiated non-small cell carcinomas.²³ Monoclonal antibody 123C3 might be useful for immunohistochemical differentiation of small cell carcinomas from non-neuroendocrine carcinomas on paraffin sections.²⁴ In contrast to the loss of one of the short arms in small cell carcinoma, retention of both short arms of chromosome 3 is observed in four patients with ESC.²⁵

Small cell lung carcinoma is thought to originate from neuroendocrine cells which are found in the epithelium of many mucosal surfaces including the gastrointestinal tract (Demellawy DE et al.). In spite of the evidence of neuroendocrine involvement, origin of ESC is still unclear as it may develop from undifferentiated airway epithelium along with the amine precursor uptake and decarboxylation (APUD) system hypothesis which proposes a common ancestral cell derived from the neural crest.²⁶ Histopathological diagnosis can be made by its classic appearance of small round to oval shaped cells with a finely granular and hyperchromatic nucleus, inconspicuous nucleoli and scanty cytoplasm on light microscopy.²⁷ The percentages of SCC samples with positive immunoreactivity were synaptophysin (Syn) 95.2%, neuronal cell adhesion molecules (CD56) 76.2%, thyroid transcriptional factor-1 (TTF-1) 71.4%, neuron specific enolase (NSE) 61.9%, chromogranin A (CgA) 61.9%, cytokeratin (CK) 57.1%, epithelial membrane antigen (EMA) 61.9%, and S100 protein (S100) 19.0%, respectively.¹⁰ SCC can show a strong and diffuse immunoreactivity for CD56 and 80% positivity for TTF-1 tumour markers.^{24,28} Histological diagnosis is based in all cases of ESC according to WHO criteria²⁹ for small cell carcinoma. Similar staging approach is applied to that used in SCLC as proposed by the Veterans' Administration Lung Group; limited disease (LD) is a tumour mass

can be encompassed within a tolerable radiation therapy port with or without regional lymph node involvement, and extensive disease (ED) includes rest of the cases.³⁰

The role of chemotherapy³¹ in SCLC is well established (Agra et al, 2005). Evidence suggests that extrapulmonary small cell carcinoma³² is also a chemosensitive disease (Levenson et al., 1981). The standard cisplatin, etoposide (PE) regimen for patients with ED-SCLC is etoposide 80mg/m², cisplatin 20 mg /m² and all are given intravenously on days 1 to 3 for every three weeks for 3 to 6 cycles. Topotecan (0.75mg/m²) combined with standard PE regimen for patients with ED-SCLC was failed to provide any benefit in terms of response and survival in patients of this group.³³ The clinical benefit of second-line therapy for relapsed small cell lung carcinoma is also limited.³⁴ However, a long survival time is observed by using combination chemotherapy with tegafur/gimeracil/oteracil potassium + cisplatin and irinotecan hydrochloride + cisplatin after gastrectomy.¹²

Among 24 ESC cases studied in their single institution and the median overall survival (OS) of 9.2 months is observed when 16 patients with LD were treated with varieties of treatment modalities and patients with ED received partly platinum based chemotherapy for which the response rate was 57% with LD- SCC of cervix showed a favourable clinical course.³⁵

Similarly, 25 of 34 ESC patients treated with surgery, followed by chemotherapy or radiotherapy showed tumour recurrence and/or systemic metastasis and they also demonstrated stage (LD vs ED) was a significant factor for overall survival.³⁹

Most institutional series report a poor outcome with surgery alone. A total of 65 small cell oesophageal cancer (SCOC) cases who had undergone surgery in combination with chemotherapy and/or radiation

therapy, a 1, 3 and 5 –year survival rates of patients in stage one and two are 76%, 30% and 18%; in contrast to 30%, 0% and 0% in patients with stage three and four. ³⁶ The largest retrospective analysis has been carried out by Brenner B et al, ³⁷ who evaluated data on 544 cases of gastrointestinal(GI) small cell carcinoma represented 0.1% to 1% of all GI malignancies. They suggested chemotherapy can achieve significant palliation, surgery may have a potential impact on long term survival of patients with locoregional disease. Four LD-SCOC patients treated at the MD Anderson Cancer Center with chemotherapy followed by radiotherapy and/ or oesophagectomy. One patient remains alive and disease-free, 57 months after diagnosis. ³⁸

The median overall survival of 17 months is reported when 18 LD-ESC patients treated with three dimensional conformal radiotherapy or intensity modulation radiation therapy and chemotherapy. No patient received prophylactic cranial irradiation (PCI). Median dose given was 62 Gy (range 23-85 Gy) with combined chemotherapy of platinum and etoposide in 88% of patients. 2(11%) patients had locoregional failure; and 14 of 18 (78%) had a distant failure. ⁴⁰ The study of 101 patients with ESC in a Canadian province found that the patients with LD had a median overall survival of 34 months compared with 2 months in patients with ED-ESC. Patients with gynaecologic small cell cancer had a median survival of 54.4 months. ⁴¹

The recent study on prophylactic cranial irradiation (PCI) seems to reduce the incidence of symptomatic brain metastases and can prolong disease-free and overall survival. They used PCI of 20 to 39 Gy in 8 to 12 fractions in all patients with small-cell lung cancer who have a response to chemotherapy. ESC is most likely to benefit in the similar way that small-cell lung cancer does. However, the role of PCI is unanswered

question for extrapulmonary neuroendocrine tumors or other neuroendocrine tumors of the lung. ⁴²

Some authors studied 90 ESC- patients treated in their institution between 1995 and 2005; female gender, limited stage disease and combined modality treatment have been found as favourable prognostic factors in multivariate analysis. ⁴³

CONCLUSION

Studies have shown wide variations on treatment modality adopted and the outcome observed. Almost all studies were of inadequate power to establish standard treatment modality. The role of radiotherapy and surgical intervention remain limited, with surgery often only being used for the treatment of localized disease. It does seem that platinum based combination chemotherapy and radiotherapy might be effective to provide local control. The role of PCI can be considered in individual basis. For cases with metastases, palliative chemotherapy with radiotherapy can be applied. The response to various treatment modalities and the median survival time observed are discouraging.

REFERENCES

1. Wu Z, Ma JY, Yang JJ, Zhao YF, Zhang SF. Primary small cell carcinoma of oesophagus: Report of 9 cases and review of literature. *World J Gastroenterol* 2004;10:3680-3682.
2. Remick SC, Ruckdeschel JC. Extrapulmonary and pulmonary small-cell carcinoma: tumor biology, therapy, and outcome. *Med Pediatr Oncol* 1992;20:89-99.
3. Demellawy DE, Samkari A, Sur M, Denardi F, Alowami S. Primary small cell carcinoma of the cecum. *Ann Diagn Pathol* 2006;10:162-165.
4. Duquid JB, Kennedy AM. Oat-cell tumors of mediasatinal glands. *J Pathological Bacteriol* 1930;33:93-9.

5. Kanat O, Qzet A, Ataergin S, Komurcu S, Onguru O. Small cell carcinoma of the large bowel: A rare, but very aggressive malignancy. *Am J Gastroenterol* 2006 Oct;101(10):2440-1.
6. Kilicansalan Akkaya B, Mustafa U, Esin O, Turker K, Gulden K. Primary small cell carcinoma of the kidney. *Urol Oncol* 2003 Jan-Feb;21(1):11-3.
7. Zachos I, Papatsoris AG, Sountoulides P, Podimatas T, Politis P, Repanti M, Vadoros G, Chrisofos M, Deliveliotis C. Primary small cell bladder carcinoma: A case report and review of the current literature 2006. *Nov-Dec*;92(6):552-4.
8. Mirza IA, Shahab N. Small cell carcinoma of the breast *Oncol* 2007 Feb;34(1):64-6.
9. Shaco-Levy R, Dyomin V, Kachko L, Sion-Vardy N, Geffen DB, Koretz M. Small cell carcinoma of the breast: Case report. *Eur J Gynaecol Oncol*. 2007;28(2):142-4.
10. Yun JP, Zhang MF, Hou JH, Tian QH, Fu J, Liang XM, Wu QL, Rong TH. Primary small cell carcinoma of the esophagus: Clinicopathological and immunohistochemical features of 21 cases. *BMC Cancer* 2007 Mar 3;7:38.
11. Hudson E, Powell J, Mukherjee S, Crosby TD, Brewster AE, Maughan TS, Bailey H, Lester JF. Small cell oesophageal carcinoma: An institutional experience and review of the literature. *Br J Cancer* 2007 Mar 12;96(5):708-11.
12. Hamano R, Hirao T, Tokuoka M, Masuzawa T, Shibata K, Kobayashi T. A case report of gastric small cell carcinoma with long survival time by adjuvant chemotherapy--reports of chemotherapy regimens for gastric small cell carcinoma. *Gan To Kagaku Ryoho* 2007 Apr;34(4):609-13.
13. Rudloff U, Amukele SA, Moldwin R, Qiao X, Morgenstern N. Small cell carcinoma arising from the proximal urethra. *Int J Urol* 2004 Aug;11 (8):674-7.
14. Emerich J, Senkus-Konefka E, Konefka T. Small cell tumor of the uterine neck. *Ginekol Pol* 1996 Apr;67(4):215-20.
15. O'Kane AM, O'Donnell ME, Shah R, Carey DP, Lee J. Small cell carcinoma of the appendix. *World J Surg Oncol* 2008 Jan 15;6:4.
16. Choi SJ, Kim JM, Han JY, Ahn SI, Kim JS, Kim L, Park IS, Chu YC. Extrapulmonary small cell carcinoma of the liver: clinicopathological and immunohistochemical findings. *Yonsei Med J* 2007 Dec 31;48(6):1066-71.
17. Jeon WJ, Chae HB, Park SM, Youn SJ, Choi JW, Kim SH. A case of primary small cell carcinoma arising from the common bile duct. *Korean J Gastroenterol* 2006 Dec;48(6):438-42. Korean.
18. Jun SR, Lee JM, Han JK, Choi BI. High-grade neuroendocrine carcinomas of the gallbladder and bile duct: Report of four cases with pathological correlation. *J Comput Assist Tomogr* 2006 Jul-Aug;30(4):604-9.
19. Takanami I, Imamura T, Yamamoto Y, Yamamoto T, Kodaira S. Long survival in small-cell (neuroendocrine) carcinoma of the mediastinum. *Scand J Thorac Cardiovasc Surg* 1996;30(3-4):179-80.
20. Walters DM, Little SC, Hessler RB, Gourin CG. Small cell carcinoma of the submandibular gland: A rare small round blue cell tumor. *Am J Otolaryngol* 2007 Mar-Apr;28(2):118-21.
21. Raina V, Milroy R, al-Dawoud A, Dunlop D, Soukop M. Extrapulmonary small cell carcinoma of bone. *Postgrad Med J* 1992 Feb;68(796):147-8.
22. Duggan DB, Anderson B, Gordon LP. Small cell carcinoma of the pancreas in association with a choledochal cyst: immunohistochemical characterization and complete response to combination chemotherapy. *Med Pediatr Oncol* 1989;17 (6):506-9.
23. Frazier SR, Kaplan PA, Loy TS. The pathology of extrapulmonary small cell carcinoma. *Semin Oncol* 2007 Feb;34(1):30-8.
24. Kaufmann O, Georgi T, Dietel M. Utility of 123C3 monoclonal antibody against CD56 (NCAM) for the diagnosis of small cell carcinomas on paraffin sections. *Hum Pathol* 1997 Dec;28(12):1373-8.
25. Johnson BE, Whang-Peng J, Naylor SL, Zbar B,

- Brauch H, Lee E, Simmons A, Russell E, Nam MH, Gazdar AF. Retention of chromosome 3 in extrapulmonary small cell cancer shown by molecular and cytogenetic studies. *J Natl Cancer Inst* 1989 Aug 16;81(16):1223-8.
26. Pearse AGE: The APUD cell concept and its implications in pathology. *Pathol Annu* 1974; 9:27-41.
 27. Remick SC, Hafez GR, Carbone PP: Extrapulmonary small cell carcinoma. A review of the literature with emphasis on therapy and outcome. *Medicine (Baltimore)* 1987;66:457-471.
 28. Kaufmann O, Flath B, Splath-Schwalbe E, Possinger K, Dietel M. Immunohistochemical detection of CD10 with monoclonal antibody 56C56 on paraffin sections. *Am J Clin Pathol* 1999;111:117-122.
 29. The World Health Organisation. Histological typing of lung tumours, second edition. *Am J Clin Pathol* 1982;77:123-136.
 30. Zelen M. Keynote address on biostatistics and data retrieval, part 3. *Cancer Chemother Rep* 1973;4:31-34.
 31. Agra Y, Pelayo M, Sacristan M, Sacristan A, Serra C, Bonfill X (2003) Chemotherapy versus best supportive care for extensive small cell lung cancer. *Cochrane Database of Systematic Reviews* 4: CD001990.
 32. Levenson RM Jr, Ihde DC, Matthews MJ, Cohen MH, Gazdar AF, Bunn PA Jr, Minna JD. Small cell carcinoma presenting as an extrapulmonary neoplasm: sites of origin and response to chemotherapy. *J Natl Cancer Inst* 1981;67:607-612.
 33. Tas F, Derin D, Guney N, Camlica H, Aydiner A, Topuz E. Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma. *Lung Cancer* 2007 Jul;57(1):79-83.
 34. Cheng S, Evans WK, Stys-Norman D, Shepherd FA. Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. *J Thorac Oncol* 2007 Apr;2(4):348-54.
 35. Jung Han Kim, Se-Hoon Lee, Jinny Park et al. Extrapulmonary Small-cell Carcinoma: A Single-institution Experience. *Japanese Journal of Clinical Oncology* 34:250-254(2004).
 36. SUN Ke-lin, HE Jie, CHENG Gui-yu, CHAI Li-xun. Management of primary small cell carcinoma of the esophagus. *Chinese Medical Journal*, 2007;Vol. 120 No. 5:355-358.
 37. Brenner B, Tang LH, Klimstra DS, Kelsen DP. Small-cell carcinomas of the gastrointestinal tract: a review. *J Clin Oncol* 2004 Jul;22(13):2730-9.
 38. Medgysey CD, Wolff RA, Putnam Jr JB, Ajani JA. Small cell carcinoma of the esophagus: the University of Texas M. D. Anderson cancer center experience and literature review. *Cancer* 2000;88:262-267.
 39. Lee SS, Lee JL, Ryu MH, Chang HM, Kim TW, Kim WK, Lee JS, Jang SJ, Khang SK, Kang YK. Extrapulmonary small cell carcinoma: single center experience with 61 patients. *Acta Oncol* 2007;46(6):846-51.
 40. Soto DE, Eisbruch A. Limited-stage extrapulmonary small cell carcinoma: Outcomes after modern chemotherapy and radiotherapy. *Cancer J* 2007 Jul-Aug;13(4):243-6.
 41. Haider K, Shahid RK, Finch D, Sami A, Ahmad I, Yadav S, Alvi R, Popkin D, Ahmed S. Extrapulmonary small cell cancer: A Canadian province's experience. *Cancer* 2006 Nov 1;107(9):2262-9.
 42. Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. *N Engl J Med* 2007;357:664-72.
 43. Yu-Lin Lin, Chih-Yuan Chung, Cheng-Shyong, Chang Jia-Shing, Wu Kuan-Ting Kuo, Sung-Hsin Kuo, Ann-Lii Cheng. Prognostic Factors in Extrapulmonary Small Cell Carcinomas. *Oncology* 2007;72:181-187.